CARDIOFLOW-B (02160) issued a profit warning, expecting a net loss of approximately 30-60 million yuan in 2024, a decrease of about 87% to 94% compared to the previous year.

CARDIOFLOW-B (02160) announced that the group expects to achieve a net loss of approximately RMB 30-60 million in 2024, a decrease of about 87% to 94% year-on-year. The announcement stated that the expected decrease in losses is mainly due to the orderly advancement of the commercialization of the VitaFlow and VitaFlow Liberty transcatheter aortic valve implantation products, as well as the AnchorMan left atrial appendage closure system and its guiding system in China, with a continuous increase in implant volume; VitaFlow Liberty transcatheter aortic valve and retrievable delivery system have obtained CE certification during the reporting period and have been sold in more than 17 countries/regions overseas, with overseas revenue increasing by more than double compared to 2023. In addition, the group focuses on business health, cost reduction, and efficiency improvement through continuous optimization of manufacturing processes, increasing production efficiency, developing multiple material suppliers through various channels, and improving the utilization of key materials to reduce product costs; at the same time, the group synergizes internal and external resources, evaluates the input-output of operating expenses, continuously improves operational efficiency, and achieves sustainable business growth healthily. Based on the completion of Series D financing of 4C Medical Technologies, Inc. (4C Medical) by the joint venture company in March 2025, and combined with its latest research and development progress, the group has reversed the previously provided impairment reserves for its equity investment in 4C Medical; in addition, the fair value change income for the convertible bonds issued by 4C Medical held by the group has been confirmed.